Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Avidity Biosciences Inc (NASDAQ: RNA) was $32.56 for the day, up 1.59% from the previous closing price of $32.05. In other words, the price has increased by $1.59 from its previous closing price. On the day, 1.18 million shares were traded. RNA stock price reached its highest trading level at $33.13 during the session, while it also had its lowest trading level at $32.025.
Ratios:
Our analysis of RNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 15.73 and its Current Ratio is at 15.73. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $70.
On March 12, 2025, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $72.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $70 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 20 ’25 when Hughes Steven George sold 9,578 shares for $31.06 per share. The transaction valued at 297,491 led to the insider holds 72,850 shares of the business.
Boyce Sarah sold 31,540 shares of RNA for $979,563 on Mar 20 ’25. The President and CEO now owns 305,871 shares after completing the transaction at $31.06 per share. On Mar 20 ’25, another insider, Flanagan W. Michael, who serves as the Chief Scientific Officer of the company, sold 11,780 shares for $31.06 each. As a result, the insider received 365,868 and left with 80,195 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 3914102784 and an Enterprise Value of 2419416576. For the stock, the TTM Price-to-Sale (P/S) ratio is 359.09 while its Price-to-Book (P/B) ratio in mrq is 2.74. Its current Enterprise Value per Revenue stands at 222.026 whereas that against EBITDA is -6.432.
Stock Price History:
The Beta on a monthly basis for RNA is 0.98, which has changed by 0.23333335 over the last 52 weeks, in comparison to a change of 0.08572841 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.56. The 50-Day Moving Average of the stock is 3.77%, while the 200-Day Moving Average is calculated to be -16.38%.
Shares Statistics:
RNA traded an average of 1.35M shares per day over the past three months and 1415320 shares per day over the past ten days. A total of 119.89M shares are outstanding, with a floating share count of 111.07M. Insiders hold about 7.61% of the company’s shares, while institutions hold 103.98% stake in the company. Shares short for RNA as of 1741910400 were 16128099 with a Short Ratio of 11.92, compared to 1739491200 on 16480495. Therefore, it implies a Short% of Shares Outstanding of 16128099 and a Short% of Float of 16.520001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
